An interventional study of eCoin Tibial Nerve Stimulation in Overactive Bladder, Urge Incontinence and Incontinence, Urinary, sponsored by Valencia Technologies Corporation. Completed at 15 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-02.
Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 333 studies in Urinary Bladder, Overactive with a site in United States — 40 open to participants now, 48 under way, 2 of them phase 3. Urinary Bladder, Overactive · United States.
Among the 333 studies in Urinary Bladder, Overactive with a site in United States, this one is the 104th largest by enrollment of the 288 interventional ones that give a count, is one of 20 that started in 2018, is one of 113 with no phase, and was the 194th registered.
860 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →40 of the 333 studies in Urinary Bladder, Overactive with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 21+ · Women only
Vensica Therapeutics Ltd. · Sites in United States
Ages 18–80 · Women only
The Cleveland Clinic · Sites in United States
Ages 18+ · Women only
Loma Linda University · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
333 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 35 · Phase 3 52 · Phase 4 71
First in 2002; this study’s year is marked. 20 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is above the median of 70 across 652 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 66 across the 288 interventional studies, 91 across the 43 observational. Of the 259 that completed or were terminated, 134 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
153 of 333 have an industry lead sponsor. The 10 most frequent:
Valencia Technologies Corporation is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Valencia Technologies Corporation has 3 studies filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
20 of the studies in Urinary Bladder, Overactive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06797245Medstar Health Research InstituteAPPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women | 2026-11 |
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT07335484Axonics, Inc.Aquarius Pilot Study to Evaluate the New Axonics Trial System | 2026-11 |
| NCT07405554Endeavor HealthZinc Supplementation With Botulinum Toxin for Overactive Bladder | 2026-12 |
| NCT05200923MedtronicNeuroPelvic Health Electrically Evoked Recording (PEER) 2 Study | 2026-12-18 |
Add all 20 to your calendar (.ics) → With an account.
Among the 333 studies in Urinary Bladder, Overactive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.
This study enrolled and implanted 133 subjects at 15 sites in the US under the original IDE.
Subjects were given the option to extend out to 3 years post activation, with annual visits at 2 and 3 years post activation (96 and 144 weeks post-activation).
Subjects who are still active in the original IDE study will be offered consecutive enrollment in the post approval study and will be given the option to receive a new implant. Subjects who are no longer active, or have exited the study will be given the option to reenter the study and complete two follow-up visits. Subjects re-entering the study will not have the option to receive a new implant. Post approval follow-up of subjects will occur through the year 5 visit (257 weeks post-activation of their original device). Reimplantation of a new eCoin would not reset their follow-up clock.
Primary Inclusion Criteria:
Primary Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: eCoin Tibial Nerve Stimulation
Subcutaneous stimulation of the tibial nerve using the eCoin device.
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Responder rate
Time frame: 48 weeks after device activation.
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.
All adverse events will be reported in all patients up to 52 weeks after implantation.
Time frame: 52 weeks after implantation.
Moderate-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.
All adverse events will be reported.
Time frame: 28 weeks after implantation
Moderate-term Effectiveness Data. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Moderate-term effectiveness data, responder rate
Time frame: 24 weeks after device activation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary
Responder rate
Time frame: 96 weeks after device activation.
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Responder rate
Time frame: 144 weeks after device activation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Responder rate
Time frame: 205 weeks after device activation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Responder rate
Time frame: 257 weeks after device activation
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events.
All adverse events will be reported in all patients up to 96 weeks after implantation.
Time frame: 96 weeks after implantation
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events
All adverse events will be reported in all patients up to 144 weeks after implantation.
Time frame: 144 weeks after implantation
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events
All adverse events will be reported in all patients up to 205 weeks after implantation.
Time frame: 205 weeks after implantation
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events
All adverse events will be reported in all patients up to 257 weeks after implantation.
Time frame: 257 weeks after implantation
| Milestone | eCoin Tibial Nerve Stimulation |
|---|---|
| Started | 133 |
| Completed | 120 |
| Not completed | 13 |
| Withdrew: Adverse event | 4 |
| Withdrew: Mri need | 3 |
| Withdrew: Device failure | 1 |
| Withdrew: Death | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Missing at random | 1 |
| Withdrew: Missing due to covid | 1 |
| Withdrew: Protocol violation | 1 |
| Milestone | eCoin Tibial Nerve Stimulation |
|---|---|
| Started | 105 |
| Completed | 41 |
| Not completed | 64 |
| Milestone | eCoin Tibial Nerve Stimulation |
|---|---|
| Started | 31 |
| Completed | 21 |
| Not completed | 10 |
Responder rate
| percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. | 68 (60 to 76) |
All adverse events will be reported in all patients up to 52 weeks after implantation.
| percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events. | 16 |
All adverse events will be reported.
| percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Moderate-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events. | 14 |
Moderate-term effectiveness data, responder rate
| percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Moderate-term Effectiveness Data. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. | 69 (61 to 77) |
Responder rate
| Percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary | 78 (67 to 87) |
Responder rate
| Percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. | 74 (57 to 87) |
Responder rate
| Percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. | 61 (39 to 80) |
Responder rate
| Percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. | 67 (43 to 85) |
All adverse events will be reported in all patients up to 96 weeks after implantation.
| Percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events. | 20 |
All adverse events will be reported in all patients up to 144 weeks after implantation.
| Percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events | 20 |
All adverse events will be reported in all patients up to 205 weeks after implantation.
| Percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events | 21 |
All adverse events will be reported in all patients up to 257 weeks after implantation.
| Percentage of participants | eCoin Tibial Nerve Stimulation |
|---|---|
| Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events | 23 |
Collected over 257 weeks post-implantation. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| eCoin Tibial Nerve Stimulation | 2/133 (1.5%) | 4/133 (3%) | 40/133 (30.1%) |
| Event | eCoin Tibial Nerve Stimulation |
|---|---|
| Implant site infectionInfections and infestations | 2/133 |
| Postoperative wound infectionInfections and infestations | 1/133 |
| Contact DermatitisSkin and subcutaneous tissue disorders | 1/133 |
| Event | eCoin Tibial Nerve Stimulation |
|---|---|
| Postoperative wound infectionInfections and infestations | 7/133 |
| Device stimulation issueProduct Issues | 6/133 |
| Incision site painInjury, poisoning and procedural complications | 5/133 |
| Device dislocationProduct Issues | 3/133 |
| Wound dehiscenceInjury, poisoning and procedural complications | 3/133 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/133 |
| Device malfunctionProduct Issues | 2/133 |
| Incision site erythemaInjury, poisoning and procedural complications | 2/133 |
| Implant site swellingGeneral disorders | 2/133 |
| Skin irritationSkin and subcutaneous tissue disorders | 2/133 |
| Age, Continuous(years) | eCoin Tibial Nerve Stimulation |
|---|---|
| Mean | 64.0 ± 11.0 |
| Sex: Female, Male(Participants) | eCoin Tibial Nerve Stimulation |
|---|---|
| Female | 131 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | eCoin Tibial Nerve Stimulation |
|---|---|
| Hispanic or Latino | 22 |
| Not Hispanic or Latino | 101 |
| Unknown or Not Reported | 10 |
| Race (NIH/OMB)(Participants) | eCoin Tibial Nerve Stimulation |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 6 |
| White | 112 |
| More than one race | 0 |
| Unknown or Not Reported | 9 |
| Region of Enrollment(participants) | eCoin Tibial Nerve Stimulation |
|---|---|
| United States | 133 |
| Urgency Urinary Incontinence (UUI) Episodes(episodes/day) | eCoin Tibial Nerve Stimulation |
|---|---|
| Mean | 4.32 ± 3.08 |
| Urinary Voids(voids/day) | eCoin Tibial Nerve Stimulation |
|---|---|
| Mean | 13.06 ± 2.67 |
| Urgency Episodes(episodes/day) | eCoin Tibial Nerve Stimulation |
|---|---|
| Mean | 8.20 ± 3.65 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2018 to primary completion in Apr 2020, 19 months.
Results were first posted in Jul 2021, 1 year 3 months after primary completion.
Of 41 industry-sponsored interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 19 months is above that.
Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Valencia Technologies Corporation